

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. – 8. (canceled)

9. (Currently Amended) A pharmaceutical composition comprising:

(i) a compound of formula I



or a pharmaceutically acceptable salt, ester, or solvate of the compound, wherein:

n is 1;

X is ~~either O or S~~;

R¹ is ~~C₄-C₉~~ straight or branched chain alkyl, C₂-C₉ straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, or heterocycle;

D is a bond, ~~C₄-C₁₀ straight or branched chain alkyl, C₂-C₁₀ alkenyl or C₂-C₁₀ alkynyl~~;


R² is COOH; ~~carboxylic acid or a carboxylic acid isostere~~

~~said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is optionally substituted with one or more substituents selected from hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl or alkynyl, aryl, aralkyl, heteroaryl, carbocycle, heterocycle, and CO₂R⁷ wherein R⁷ is hydrogen, C₁-C₉ straight or branched chain alkyl or C₂-C₉ straight or branched chain alkenyl; and~~

(ii) a pharmaceutically acceptable carrier.

10. – 12. (Cancelled)

13. (Currently Amended) The pharmaceutical composition of claim 9, wherein the compound is selected from the group consisting of compounds of Formula (I) 1, 3, 5, 8, 11, 14, 17, 21, 24 32, 34, 38 40, 44, 45, 47 52, 62, 64 68, 73 98, 101, 102, 106, 108 117 and 119 137 of Tables I, II and III



,wherein,

(a) D is a bond, R₂ is COOH, and

X, n, and R₁ are defined as follows:

No.	X	n	R ₁

<u>1</u>	<u>Q</u>	<u>1</u>	<u>3,4,5-trimethylphenyl</u>
<u>3</u>	<u>Q</u>	<u>1</u>	<u>tert-butyl</u>
<u>5</u>	<u>Q</u>	<u>1</u>	<u>cyclopentyl</u>
<u>8</u>	<u>Q</u>	<u>1</u>	<u>cyclohexyl</u>
<u>11</u>	<u>Q</u>	<u>1</u>	<u>cycloheptyl</u>
<u>14</u>	<u>Q</u>	<u>1</u>	<u>2-thienyl</u>
<u>17</u>	<u>Q</u>	<u>1</u>	<u>2-furyl</u>
<u>21</u>	<u>Q</u>	<u>1</u>	<u>1,1-dimethylpentyl</u>

;

or


(b) n, X, D, R₂, and R₁ are defined as follows:

<u>No.</u>	<u>n</u>	<u>X</u>	<u>D</u>	<u>R₂</u>	<u>R₁</u>
<u>83</u>	<u>1</u>	<u>Q</u>	<u>bond</u>	<u>COOH</u>	<u>α-Methylphenyl</u>
<u>84</u>	<u>1</u>	<u>Q</u>	<u>bond</u>	<u>COOH</u>	<u>4-Methylphenyl</u>
<u>137</u>	<u>1</u>	<u>Q</u>	<u>bond</u>	<u>COOH</u>	<u>1,1-dimethylpropyl</u>

14. – 82. (Cancelled)

83. (New) A pharmaceutical composition comprising

(i) a compound of formula I



or a pharmaceutically acceptable salt, ester, or solvate of the compound, wherein:

X is O;

n is 1;

D is a bond;

R² is -COOH;

R¹ is 1,1-dimethylpropyl, and

(ii) a pharmaceutically acceptable carrier.